유럽 차세대 유방암 진단 및 스크리닝 시장 : 분석 및 예측(2023-2032년)

“The Europe Next-Generation Breast Cancer Diagnostic and Screening Market Expected to Reach $2.57 Billion by 2032.”

Introduction to Europe Next-Generation Breast Cancer Diagnostic and Screening Market

The Europe next-generation breast cancer diagnostic and screening market was valued at $0.84 billion in 2023 and is expected to reach $2.57 billion by the end of 2032, registering a CAGR of 13.20% during the forecast period 2023-2032. The growth in the next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.

Market Introduction

The European Next-Generation Breast Cancer Diagnostic and Screening Market is experiencing significant growth driven by factors such as the region's early adoption of advanced medical technologies, a high prevalence of breast cancer, and a strong healthcare infrastructure. European countries prioritize breast cancer awareness and screening, fostering the integration of innovative biomarkers and genetic testing into diagnosis. Collaborations between healthcare institutions, research organizations, and industry players further enhance diagnostic accuracy and efficiency, contributing to improved patient outcomes. These efforts reflect the region's commitment to addressing breast cancer challenges and are expected to sustain market growth and enhance breast cancer management in Europe.

Market Segmentation:

Segmentation 1: by Country

• Germany
• France
• U.K.
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the Europe next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.

Competitive Strategy: Key players in the Europe next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Oncology Molecular Diagnostic Market

• 1.1. Overview
• 1.2. Cancer Type
• 1.3. Technology
• 1.4. Market Dynamics
• 1.5. Regulatory-Approved Products

2. Regions

• 2.1. Europe
  • 2.1.1. Key Findings
  • 2.1.2. Market Dynamics
    • 2.1.2.1. Impact Analysis
  • 2.1.3. Market Sizing and Forecast
    • 2.1.3.1. Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
      • 2.1.3.1.1. Germany
        • 2.1.3.1.1.1. Market Dynamics
        • 2.1.3.1.1.2. Market Sizing and Forecast
      • 2.1.3.1.2. France
        • 2.1.3.1.2.1. Market Dynamics
        • 2.1.3.1.2.2. Market Sizing and Forecast
      • 2.1.3.1.3. U.K.
        • 2.1.3.1.3.1. Market Dynamics
        • 2.1.3.1.3.2. Market Sizing and Forecast
      • 2.1.3.1.4. Italy
        • 2.1.3.1.4.1. Market Dynamics
        • 2.1.3.1.4.2. Market Sizing and Forecast
      • 2.1.3.1.5. Spain
        • 2.1.3.1.5.1. Market Dynamics
        • 2.1.3.1.5.2. Market Sizing and Forecast
      • 2.1.3.1.6. Rest-of-Europe
        • 2.1.3.1.6.1. Market Dynamics
        • 2.1.3.1.6.2. Market Sizing and Forecast

3. Markets - Competitive Benchmarking

• 3.1. Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
• 3.2. Company Profiles
  • 3.2.1. Agendia Inc.
    • 3.2.1.1. Company Overview
    • 3.2.1.2. Role of Agendia Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 3.2.1.3. Recent Developments
    • 3.2.1.4. Analyst Perception
  • 3.2.2. CENTOGENE N.V.
    • 3.2.2.1. Company Overview
    • 3.2.2.2. Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 3.2.2.3. Financials
    • 3.2.2.4. Recent Developments
    • 3.2.2.5. Analyst Perception
  • 3.2.3. F. Hoffmann-La Roche Ltd.
    • 3.2.3.1. Company Overview
    • 3.2.3.2. Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 3.2.3.3. Financials
    • 3.2.3.4. Recent Developments
    • 3.2.3.5. Analyst Perception